Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

被引：0
|
作者：
Lim, M. [1 ]
Omuro, A. [2 ]
Vlahovic, G. [3 ]
Reardon, D. A. [4 ,5 ]
Sahebjam, S. [6 ]
Cloughesy, T. [7 ]
Baehring, J. [8 ]
Butowski, N. [9 ]
Potter, V. [10 ]
Zwirtes, R. [10 ]
Paliwal, P. [10 ]
Carleton, M. [10 ]
Sampson, J. [3 ]
Brandes, A. A. [11 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Metastat Brain Tumor Ctr, Baltimore, MD USA
[2] Mem Sloan Kettering Canc Ctr, Neurol, 1275 York Ave, New York, NY 10021 USA
[3] Duke Univ, Med Ctr, Preston Robert Tisch Brain Tumor Ctr Duke, Durham, NC USA
[4] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Boston, MA USA
[6] Univ S Florida, H Lee Moffitt Canc Ctr, Oncol, Tampa, FL 33682 USA
[7] Univ Calif Los Angeles, Neurol Oncol, Los Angeles, CA USA
[8] Yale Sch Med, Neurol, New Haven, CT USA
[9] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA
[10] Bristol Myers Squibb Co, Oncol, Princeton, NJ USA
[11] AUSL IRCCS Inst Neurol Sci, Neurol, Bologna, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3250
引用
收藏
页数：1
相关论文
共 50 条
  • [31] BEVACIZUMAB (BV) IN COMBINATION TO TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A PHASE 2 TRIAL
    Desjardins, Annick
    Reardon, David A.
    Peters, Katherine B.
    Herndon, James
    Kirkpatrick, John
    Gururangan, Sridharan
    Sampson, John H.
    Friedman, Allan H.
    Friedman, Henry
    Vredenburgh, James J.
    NEURO-ONCOLOGY, 2009, 11 (05) : 634 - 634
  • [32] NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients
    Sarkaria, J. N.
    Galanis, E.
    Wu, W.
    Giannini, C.
    Jaeckle, K. A.
    Doyle, L.
    Uhm, J.
    Brown, P.
    Dietz, A. B.
    Buckner, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] FINAL EFFICACY AND SAFETY RESULTS FROM AVAglio, A PHASE III TRIAL OF BEVACIZUMAB (BEV) PLUS TEMOZOLOMIDE (TMZ) ANDRADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA
    Chinot, Olivier L.
    Wick, Wolfgang
    Mason, Warren
    Henriksson, Roger
    Saran, Frank
    Nishikawa, Ryo
    Carpentier, Antoine F.
    Khe Hoang-Xuan
    Kavan, Petr
    Cernea, Dana
    Brandes, Alba A.
    Hilton, Magalie
    Kerloeguen, Yannick
    Guijarro, Abajo
    Cloughsey, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 105 - 106
  • [34] PHASE I/II STUDY TO EVALUATE THE SAFETY AND CLINICAL EFFICACY OF ATEZOLIZUMAB (ATEZO) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Weathers, Shiao-Pei
    Kamiya-Matsuoka, Carlos
    Harrison, Rebecca
    Liu, Diane
    Sanqui, Edmund
    Dervin, Shannon
    Yun, Cindy
    Loghin, Monica
    Penas-Prado, Marta
    Majd, Nazanin
    Yung, W. K. Alfred
    O'Brien, Barbara
    de Groot, John
    NEURO-ONCOLOGY, 2020, 22 : 35 - 35
  • [35] Safety of TTFields and radiotherapy (RT) for newly diagnosed glioblastoma: Interim safety results from a pilot study
    Grossman, Rachel
    Ram, Zvi
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Mature results of a phase I/IIA trial of the integrin inhibitor cilengitide (EMD121974) added to standard concomitant and adjuvant temozolomide and radiotherapy (TMZ/RT) for newly diagnosed glioblastoma (GBM)
    Stupp, Roger
    Goldbrunner, Roland
    Neyns, Bart
    Schlegel, Uwe
    Clement, Paul
    Grabenbauer, Gerhard
    Hegi, Monika
    Nippgen, Johannes
    Picard, Martin
    Weller, Michael
    NEURO-ONCOLOGY, 2007, 9 (04) : 517 - 517
  • [37] Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial
    Supriya Mallick
    Subhash Gupta
    Adila Amariyil
    Haresh Kunhiparambath
    M. A. Laviraj
    Seema Sharma
    Hari Krishna Raju Sagiraju
    Pramod Kumar Julka
    Dayanand Sharma
    Goura Kishor Rath
    Journal of Neuro-Oncology, 2023, 164 : 141 - 146
  • [38] Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: updated results from phase II HART-GBM trial
    Mallick, Supriya
    Gupta, Subhash
    Amariyil, Adila
    Kunhiparambath, Haresh
    Laviraj, M. A.
    Sharma, Seema
    Sagiraju, Hari Krishna Raju
    Julka, Pramod Kumar
    Sharma, Dayanand
    Rath, Goura Kishor
    JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (1) : 141 - 146
  • [39] Phase II Trial of Temozolomide (TMZ), Motexafin Gadolinium (MGd), and 60 Gy Fractionated Radiation (RT) for Newly Diagnosed Supratentorial Glioblastoma (GBM): Results of RTOG 0513
    Brachman, D. G.
    Wang, M.
    Ashby, L. S.
    Thomas, T. A.
    Dunbar, E. M.
    Rockhill, J. K.
    Khuntia, D.
    Bovi, J. A.
    Macher, M. S.
    Mehta, M. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S129 - S130
  • [40] Efficacy and safety of bevacizumab (By) plus standard combination temozolomide (T) and radiotherapy (RI) in newly diagnosed glioblastoma: Final results from AVAglio
    Wick, W.
    Cloughesy, T.
    Henrikkson, R.
    Saran, F.
    Mason, W.
    Nishikawa, R.
    Hilton, M.
    Abrey, L.
    Chinot, O.
    ONKOLOGIE, 2013, 36 : 94 - 94
12345